BioHealth News Archive
United Therapeutics Announces FDA Approval Of XPS™ And Steen Solution™ Used To Perform Centralized Ex-Vivo Lung Perfusion Services | BioSpace
United Therapeutics Corporation (Nasdaq: UTHR) today announced that its collaborator, XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (STO: XVIVO), has received Premarket…
Read More
GSK receives US approval of Benlysta for intravenous use in children with lupus aged five years and above | Antibodies | News Channels
GSK today announced that the US Food and Drug Administration (FDA) has approved, under priority review, the use of the intravenous (IV) formulation of…
Read More
Sirnaomics closes Series C funding round – Washington Business Journal
Sirnaomics Inc. has taken in yet another $11 million in investments, closing a Series C funding round that totaled $47 million. {iframe}https://www.bizjournals.com/washington/news/2019/04/26/sirnaomics-closes-47-million-funding-round.amp.html{/iframe}
Read More
University Of Maryland Medical School Uses New Drone To Transport Donor Organs – CBS Baltimore
A pioneering medical breakthrough that will help organ transplant recipients was announced by the University of Maryland Medical School. Drone technology was developed by…
Read More
Kite’s CAR-T manufacturing gets another boost with new Maryland facility | FiercePharma
With an FDA approval for its pricey CAR-T therapy Yescarta under its belt and more treatments in the pipeline, Gilead’s Kite Pharma was on…
Read More
THRIVE 2019: CREATING THE FUTURE OF BIOSCIENCE IN VIRGINIA
Every two years leader of the life science industry gather from across the state to connect, celebrate, learn, inspire, imagine, and drive forward the…
Read More
GSK ramps up investment into Shingrix production
GSK announces that it will spend $100m to expand production capacity for components of Shingrix, amid a US market where demand outstrips supply of…
Read More
Kite Pharma plans manufacturing facility in Frederick County – Technical.ly Baltimore
A Santa Monica, Calif.-based biopharmaceutical company plans to open a facility where it will produce cell therapy treatments in Maryland’s Frederick County. Kite Pharma…
Read More
IBBR investigator to lead $3.5M NIH-funded project to study immune response to HIV-1
Researchers at the Institute for Bioscience and Biotechnology Research (IBBR) recently received $3.5M from the National Institutes of Health (NIH) to advance understanding of…
Read More
Built For Bio: Pat Larrabee, President of Facility Logix
MCEDC learns how Pat’s love for science drove her to found a company in Montgomery County, MD that delivers the cutting-edge buildings innovators need…
Read More
Autolus Therapeutics Receives FDA Orphan Drug Designation for AUTO3 for Treatment of Acute Lymphoblastic Leukemia Nasdaq:AUTL
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that the United States…
Read More
Illumina Accelerator Invests in Four New Startups – GenomeWeb
Illumina has added four genomics startups to its accelerator program, marking its ninth funding round, the company said on Tuesday. {iframe}https://www.genomeweb.com/sequencing/illumina-accelerator-invests-four-new-startups?utm_source=Sailthru&utm_medium=email&utm_campaign=GWDN%20Wed%20AM%20A/B%20Test%202019-04-24&utm_term=GWDN%20A/B%20Test#.XMcZGpNKhYg{/iframe}
Read More
NIST Releases Findings on Increasing the Innovation Impacts of Federally Funded R&D | NIST
Today, the U.S. Department of Commerce’s National Institute of Standards and Technology announced 15 key findings from a final version of a new “green…
Read More
Kite to Open Cell Therapy Manufacturing Facility in Frederick County Creating Significant Job Opportunities In Maryland – BioBuzz
Kite Pharma, a California-based biopharmaceutical company that develops innovative cancer immunotherapies, announced plans today to open a new biologics manufacturing facility in Frederick County…
Read More
GlycoMimetics Announces Enrollment of First Patient in NCI-Sponsored Phase 3 Trial of Uproleselan in AML – Business Wire
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today dosing of the first patient in a Phase 3 clinical trial being conducted under the auspices of a…
Read More